BBOT · Insider Trading
BridgeBio Oncology Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by BBOT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-23 | Marc Cobo | Principal Accounting Officer | F | −203 | −$544 |
| 2026-10-05 | Marc Cobo | Principal Accounting Officer | F | −126 | −$496 |
| 2026-10-05 | Pedro Beltran | President and CEO | F | −1,047 | −$4.13K |
| 2026-10-05 | Idan Elmelech | COO & Principal Financial Ofcr | F | −343 | −$1.35K |
| 2026-10-05 | Yong Ben | Chief Med & Dev Officer | F | −1,047 | −$4.13K |
| 2026-09-14 | Marc Cobo | Principal Accounting Officer | MIXED | +8,835 | −$1.12K |
| 2026-07-06 | Marc Cobo | Principal Accounting Officer | F | −125 | −$975 |
| 2026-07-06 | Yong Ben | Chief Med & Dev Officer | F | −1,047 | −$8.17K |
| 2026-07-06 | Pedro Beltran | President and CEO | F | −1,047 | −$8.17K |
| 2026-07-06 | Bihua Chen | Director | J | — | — |
| 2026-07-06 | Idan Elmelech | COO & Principal Financial Ofcr | F | −343 | −$2.68K |
| 2026-06-18 | Raymond J. Kelleher | Director | A | +31,675 deriv. | — |
| 2026-06-18 | Peter F Lebowitz | Director | A | +7,289 deriv. | — |
| 2026-06-18 | Bihua Chen | Director | A | +31,675 deriv. | — |
| 2026-06-18 | Jake Bauer | Director | A | +31,675 deriv. | — |
| 2026-06-18 | Frank McCormick | Director | A | +31,675 deriv. | — |
| 2026-06-18 | Neil Kumar | Director | A | +31,675 deriv. | — |
| 2026-06-18 | Praveen P. Tipirneni | Director | A | +31,675 deriv. | — |
| 2026-05-12 | Pedro Beltran | President and CEO | A | +1,103,837 deriv. | — |
| 2026-05-12 | Idan Elmelech | COO & Principal Financial Ofcr | A | +758,222 deriv. | — |
| 2026-05-05 | Pedro Beltran | President and CEO | F | −1,047 | −$9.45K |
| 2026-05-05 | Yong Ben | Chief Med & Dev Officer | F | −1,047 | −$9.45K |
| 2026-05-05 | Uneek Mehra | — | F | −524 | −$4.73K |
| 2026-03-26 | Peter F Lebowitz | Director | A | +63,350 deriv. | — |
| 2026-03-12 | Uneek Mehra | Chief Financial Officer | A | +23,330 | — |
| 2026-03-12 | Pedro Beltran | Chief Scientific Officer | A | +46,670 | — |
| 2026-03-12 | Yong Ben | Chief Med & Dev Officer | A | +46,670 | — |
| 2026-01-05 | Eli M. Wallace | Chief Executive Officer | A | +1,114,400 deriv. | — |
| 2025-12-12 | Eli M. Wallace | Chief Executive Officer | D | −1,114,400 deriv. | — |
| 2025-10-16 | BridgeBio Pharma, Inc. | 10%+ Owner | J | +1,569,440 | — |
| 2025-10-06 | Eli M. Wallace | Chief Executive Officer | A | +1,614,400 deriv. | — |
| 2025-08-28 | Eli M. Wallace | Chief Executive Officer | A | +499,731 deriv. | — |
| 2025-08-28 | Uneek Mehra | Chief Financial Officer | A | +633,570 deriv. | — |
| 2025-08-28 | Praveen P. Tipirneni | Director | A | +52,269 deriv. | — |
| 2025-08-28 | Yong Ben | Chief Med & Dev Officer | A | +357,177 deriv. | — |
| 2025-08-28 | Pedro Beltran | Chief Scientific Officer | A | +357,177 deriv. | — |
| 2025-08-28 | Frank McCormick | Director | A | +91,076 deriv. | — |
| 2025-08-28 | Jake Bauer | Director | A | +138,193 deriv. | — |
| 2025-08-13 | Bihua Chen | Director | MIXED | +14,969,594 | +$75.00M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| BridgeBio Pharma, Inc. | 10%+ Owner | 14,589,846 | $38.52M |
| Bihua Chen | Director | 1,905,046 | $5.03M |
| Yong Ben | Chief Med & Dev Officer | 43,529 | $114.92K |
| Pedro Beltran | President and CEO | 43,529 | $114.92K |
| Uneek Mehra | Chief Financial Officer | 22,806 | $60.21K |
| Idan Elmelech | COO & Principal Financial Ofcr | 14,152 | $37.36K |
| Marc Cobo | Principal Accounting Officer | 13,812 | $36.46K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BBOT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.